- American City Business Journals•10 months ago
Launching its third new health care company in a month, Flagship Ventures is putting $25 million into a startup that wants to treat diseases by putting new genes into red blood cells. Avak Kahvejian, CEO of newly-launched Rubius Therapeutics and a partner at Flagship’s VentureLabs incubator, said in an interview that the approach is “really a new way of thinking about treating diseases.” It can also apply (in theory) to any type of disease. “The only thing that limits us is, one, our imagination, and two, the genes we can put into red blood cells,” said Kahvejian, who previously worked in business development roles at another Flagship startup, Helicos BioSciences.
We're sorry this is all we were able to find about this topic.
. Currency in USD
|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52wk Range||undefined - undefined|
|1y Target Est||N/A|
|P/E Ratio (ttm)||N/A|
|Avg Vol (3m)||N/A|
|Dividend & Yield||N/A (N/A)|